|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficient engagement with the envelope glycoprotein membrane-proximal external region (MPER) results in robust blocking of viral infection by a class of broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV).
|
31787208 |
2020 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attachment of envelope glycoprotein gp120 to the host cell receptor CD4 is the first step during the human immunodeficiency virus-1 (HIV-1) entry into the host cells that makes it a promising target for drug design.
|
31792886 |
2020 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used long-read, deep-sequenced data of full-length HCV envelope glycoprotein, longitudinally sampled from acute to chronic HCV infection to investigate the underlying viral population and evolutionary dynamics.
|
30602023 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, this effort has proven challenging because HCV evades neutralizing antibodies (NAbs) through molecular features of viral envelope glycoprotein E2, including hypervariable region 1 (HVR1) and N-linked glycans.
|
31040211 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we constructed genetic vaccines based on novel recombinant adeno‑associated viral (rAAV) vectors (AAV2/8 or AAV2/rh32.33) that express the envelope glycoprotein E2 from the HCV genotype 1b.
|
30569131 |
2019 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus.
|
31116791 |
2019 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Assembly of infectious hepatitis C virus (HCV) particles is known to involve host lipoproteins, giving rise to unique lipo-viro-particles (LVPs), but proteome studies now suggest that additional cellular proteins are associated with HCV virions or other particles containing the viral envelope glycoprotein E2.
|
30880226 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our phase I study with recombinant HCV E1/E2 envelope glycoprotein (EnvGPs) as a candidate vaccine did not induce a strong immune response in volunteers.
|
29443378 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overcoming Challenges of Hepatitis C Virus Envelope Glycoprotein Production in Mammalian Cells.
|
30593635 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cumulative evidence supports the importance of antibodies targeting the HCV E2 envelope glycoprotein to facilitate viral clearance.
|
30651366 |
2019 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
An efficient and specific liquid chromatography (LC)-based assay was developed to monitor the production of recombinant HIV-1 trimeric envelope glycoprotein (HIV Env trimer), a candidate vaccine for HIV-1 infection, in cell culture media to support scale-up process development.
|
31060952 |
2019 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Viral entry, which involves the interaction of the surface envelope glycoprotein, gp120, with the cellular receptor, CD4, is the first step of HIV-1 infection.
|
31424369 |
2019 |
|
HIV-1 infection
|
0.100 |
Biomarker
|
disease |
BEFREE |
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have promising utility in prevention and treatment of HIV-1 infection, and several are currently undergoing clinical trials.
|
31604961 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to these anti-cancer properties, man-specific seaweed lectins have been widely used as potent human immunodeficiency virus (HIV-1)-inactivating proteins, due to their capacity to specifically interact with the envelope glycoprotein gp120 and prevent the virion infectivity of HIV-1 towards the host CD4+ T-lymphocyte cells in vitro.
|
31357490 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SOS change exerted more subtle, context-dependent effects on Env conformation and function.<b>IMPORTANCE</b> The human immunodeficiency virus type 1 (HIV-1) envelope proteins (Envs) bind receptors on the host cell and change shape to allow the virus to enter the cell.
|
30944182 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Passively administered broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have been shown to protect non-human primates (NHPs) against chimeric simian-human immunodeficiency virus (SHIV) infection.
|
31513771 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Binding to the receptor CD4 triggers entry-related conformational changes in the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer, (gp120/gp41)<sub>3</sub> Soluble versions of HIV-1 Env trimers (sgp140 SOSIP.664) stabilized by a gp120-gp41 disulfide bond and a change (I559P) in gp41 have been structurally characterized.
|
30429345 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutralizing antibodies against human immunodeficiency virus subtype 1 (HIV-1) bind to its envelope glycoprotein (Env).
|
31607367 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the entry process, the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer undergoes a sequence of conformational changes triggered by both CD4 and coreceptor engagement.
|
30650070 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
An envelope glycoprotein, gp41, is crucial for the entry of human immunodeficiency virus (HIV) into the host cell.
|
31345037 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The N-terminal fusion peptide (FP) of the human immunodeficiency virus (HIV)-1 envelope glycoprotein (Env) gp41 subunit plays a critical role in cell entry.
|
30770829 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
PF-68742 is a small molecule that inhibits the infection of a subset of HIV-1 strains by interfering with an Env function other than receptor binding.
|
31391272 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus (HIV-1) entry is initiated by the binding between the viral envelope glycoprotein gp120 and the host receptor CD4, and followed by reduction of structural disulfides of gp120 and CD4.
|
30948772 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The envelope glycoprotein gp120 is exposed on the surface of the HIV envelope, essential for virus entry into cells by the attachment to specific cell surface receptors.
|
30873925 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the molecular docking of virus-entry molecule (gp120 envelope glycoprotein) revealed the key interacting residues of the protein (cellular receptor, CD4) and the site-moiety preferences of colchicine derivatives as HIV entry inhibitors for binding to HIV structure.
|
30251609 |
2019 |